Trial Information

Summary: A phase 2 B dose ranging research study to evaluate the response eficacy and safety of five doses of an investigational once daily inhaled dry powder compared to placebo in subjects with COPD.

This is a 7 week research study requiring a minimum of 9 clinic visits. The study will require blood work as well as EKGs and pulmonary function tests.

Patient Inclusion Criteria: All patients must have a clinical diagnosis of COPD, be male or female, current or former smokers and be between the ages of 40 and 80.

Patient Exclusion Criteria: Patients may not have sleep apnea that requires CPAP or a severe disease that requires the use of long term oxygen.

If you would like to learn more about participating in this study, please send an e-mail message using the form below.